0000000000068932

AUTHOR

Stelvio Ballanti

showing 4 related works from this author

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical exper…

2020

No abstract available

Oncologymedicine.medical_specialtyElotuzumab lenalidomide dexamethasone salvage therapy multiple myelomaSalvage therapyAntibodies Monoclonal HumanizedAntibodiesDexamethasoneEfficacyInternal medicineMonoclonalAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalElotuzumabLetters to the EditorElotuzumab lenalidomide dexamethasone multiple myelomaHumanizedLenalidomideMultiple myelomaRetrospective StudiesLenalidomideSalvage Therapybusiness.industryRetrospective cohort studyHematologymedicine.diseaseClinical trialItalyAntibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Italy; Lenalidomide; Retrospective Studies; Salvage Therapy; Multiple MyelomaMultiple Myelomabusinessmedicine.drug
researchProduct

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma pat…

2021

The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categori…

Oncologymedicine.medical_specialtySalvage therapyAntibodies Monoclonal HumanizedDexamethasoneSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansElotuzumabLenalidomideDexamethasoneMultiple myelomaLenalidomideRetrospective StudiesSalvage Therapycarfilzomibbusiness.industryHazard ratioHematologyGeneral Medicinemedicine.diseaseCarfilzomibelotuzumabmultiple myelomachemistryCohortbusinessOligopeptidesmedicine.drug
researchProduct

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide…

2022

The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (…

multiple myelomaCancer ResearchcarfilzomibOncologylenalidomidesurvival.elotuzumabprognosiprognostic scorerelapsed/refractoryFrontiers in oncology
researchProduct

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective cli…

2022

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyse…

Cancer Researchlenalidomidedexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapydexamethasoneHematologyGeneral MedicineAntibodies Monoclonal HumanizedelotuzumabThalidomidemultiple myelomaOncologyAntineoplastic Combined Chemotherapy ProtocolsHumanssalvage therapySettore MED/15 - Malattie del SangueFollow-Up StudiesRetrospective StudiesHematological Oncology
researchProduct